Indian pharma stocks reel as US tariffs loom, sparking investor concerns

8 May 2025

As the US government, under President Donald Trump, is on the verge of announcing significant new tariffs on pharmaceutical imports, Indian drug-maker stocks continue to take a hammering on the bourses. Experts state the selloff is triggered by concerns that Indian pharma exporters, heavily reliant on the US market, could face business headwinds, reports The Pharma Letter’s India correspondent.

Indian pharmaceutical stocks have seen a decline following President Trump's renewed tariff threats on pharma imports. On May 7, India's Nifty Pharma index fell by 2.11%, with several major drug-makers registering losses.

Among the biggest losers were Lupin (BOM: 500257) and Aurobindo Pharma (BOM: 524804) which fell by more than 3%. Cipla (BOM: 500087) declined by 2% and Sun Pharma (BOM: 524715) slipped 1.9%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK